Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biodistribution of TH-SC01 in Perianal Fistula
NCT06429241Phase 1Recruiting
- Sponsor
- Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd.
- Start
- Apr 2024
- Primary completion
- Nov 2024
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TH-SC01 in perianal fistula and Crohn's disease, sponsored by Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd. Primary endpoint: Standardized uptake value. Started Apr 2024; status: recruiting.
02
Drugs
TH-SC01
03
Conditions
perianal fistulaCrohn's disease
Beyond the preview
Go deeper on NCT06429241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06429241.